Work

HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease

Year: 2015

Type: article

Abstract: In vitro and animal studies continue to elucidate the mechanisms of fibrosis and have led to advancements in treatment for idiopathic pulmonary fibrosis and cirrhosis, but the search for treatments for renal fibrosis has been more disappointing. Here, we will discuss homeodomain-interacting-protein kinase 2 (HIPK2), a novel regulator of fibrosis that acts upstream of major fibrosis signaling pathways. Its key role in renal fibrosis has been validated in vitro and in several murine models of chronic kidney diseases (CKD).

Source: Frontiers in Physiology

DOI: 10.3389/fphys.2015.00132

Authors: Melinda M. Nugent, Kyung Lee, John Cijiang He

Institutions: Icahn School of Medicine at Mount Sinai, James J. Peters VA Medical Center

Language: English

Topic: Chronic Kidney Disease and Diabetes

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801